Vestal Point Capital LP Takes $31.56 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vestal Point Capital LP bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, HoldingsChannel.com reports. The firm bought 3,350,000 shares of the biopharmaceutical company’s stock, valued at approximately $31,557,000. Amicus Therapeutics makes up 1.9% of Vestal Point Capital LP’s investment portfolio, making the stock its 22nd biggest holding.

Several other large investors also recently made changes to their positions in FOLD. Virtus Fund Advisers LLC acquired a new stake in shares of Amicus Therapeutics in the 4th quarter valued at about $29,000. Covestor Ltd lifted its position in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 2,312 shares in the last quarter. R Squared Ltd bought a new position in Amicus Therapeutics in the 4th quarter valued at about $79,000. KBC Group NV lifted its position in Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,120 shares in the last quarter. Finally, Sciencast Management LP bought a new position in Amicus Therapeutics in the 4th quarter valued at about $100,000.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock opened at $6.43 on Monday. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65. The company’s 50 day moving average price is $7.37 and its two-hundred day moving average price is $8.88. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The stock has a market cap of $1.98 billion, a P/E ratio of -35.72, a P/E/G ratio of 1.51 and a beta of 0.64.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. UBS Group raised their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, May 2nd. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 5th. The Goldman Sachs Group dropped their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $16.22.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.